National Institute for Health and Care Excellence (NICE) has recommended Keytruda, alongside a combination of pemetrexed and platinum chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC). This combination is recommended for untreated, metastatic NSCLC in adults whose tumors have no epidermal growth factor (EGFR) positive or anaplastic lymphoma kinase (ALK) positive mutations. Previously,